PROSTATE CANCER · White paper
Prostate Cancer Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About prostate cancer — and why its trials are hard
Prostate cancer is the second most common cancer among men in the United States, with about 1 in 8 men diagnosed in their lifetime and roughly 299,000 new cases projected for 2024. Most tumors are adenocarcinomas arising in gland cells, ranging from indolent, screen-detected disease to aggressive metastatic cancer. The introduction of PSA testing in the late 1980s transformed early detection, and mortality has declined thanks to earlier diagnosis and more effective therapy. Treatment spans active surveillance, surgery and radiation for localized disease, and a deep systemic armamentarium for advanced disease: androgen deprivation therapy (GnRH agonists/antagonists), androgen-receptor pathway inhibitors (abiraterone, enzalutamide, apalutamide), taxane chemotherapy (docetaxel, cabazitaxel), PARP inhibitors for HRR/BRCA-mutated tumors (olaparib, rucaparib), the radioligand Lu-177-PSMA-617, radium-223, sipuleucel-T immunotherapy and bone-targeting agents. Clinical trials increasingly rely on time-to-event endpoints such as overall survival, radiographic progression-free survival and metastasis-free survival, while contending with PSA variability, treatment resistance, tumor heterogeneity and long follow-up requirements. Biomarker-driven and combination strategies now shape modern trial design.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Abiraterone acetate (Zytiga) | 2011 | Metastatic CRPC (post-docetaxel) and metastatic high-risk CSPC; CYP17 inhibitor | COU-AA-301 | Overall survival | Median OS 14.8 vs 10.9 months vs placebo+prednisone (HR ~0.65) |
| Enzalutamide (Xtandi) | 2012 | Metastatic CRPC (post-docetaxel initially); androgen receptor inhibitor | AFFIRM (NCT00974311) | Overall survival | Median OS 18.4 vs 13.6 months vs placebo (HR ~0.63) |
| Apalutamide (Erleada) | 2018 | Non-metastatic CRPC; androgen receptor inhibitor | SPARTAN (NCT01946204) | Metastasis-free survival | Median MFS 40.5 vs 16.2 months (HR 0.28) |
| Docetaxel (Taxotere) | 2004 | Metastatic CRPC; taxane chemotherapy | TAX 327 | Overall survival | Median OS 18.9 vs 16.5 months vs mitoxantrone (every-3-weeks; HR 0.76) |
| Olaparib (Lynparza) | 2020 | mCRPC with HRR/BRCA gene mutations; PARP inhibitor | PROfound | Radiographic progression-free survival | rPFS 7.4 vs 3.6 months (BRCA/ATM cohort; HR ~0.34) |
| Lutetium-177 vipivotide tetraxetan (Lu-177-PSMA-617) (Pluvicto) | 2022 | PSMA-positive mCRPC after ARPI and taxane; radioligand therapy | VISION | Overall survival | Median OS 15.3 vs 11.3 months plus standard care (HR ~0.62) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in prostate cancer development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Enzalutamide + abiraterone combination — NCT01995513 | Combination was safe but did not improve progression-free survival over abiraterone/prednisone alone in mCRPC | No additive benefit from combining two androgen-axis agents; overlapping mechanisms |
| Bicalutamide 150 mg monotherapy — Early Prostate Cancer (EPC) programme | In localized watchful-waiting patients showed a trend toward decreased survival vs placebo (HR ~1.16); 150 mg not approved as monotherapy | Harm outweighed benefit in low-risk/localized disease; treatment discontinued by monitoring board in metastatic subset |
| Apalutamide (neoadjuvant, non-castrating) — NCT03412396 | Pre-operative anti-androgen neoadjuvant therapy before prostatectomy did not reduce adverse pathology | Failed to meet primary pathology endpoint; insufficient effect in the neoadjuvant window |
Choosing the right endpoint
Primary endpoints that matter in prostate cancer trials
- Overall survival (OS) — Gold-standard efficacy endpoint; requires large samples and long follow-up and can be confounded by subsequent therapies (crossover)
- Radiographic progression-free survival (rPFS) — Surrogate using PCWG/RECIST imaging criteria; needs consistent, blinded imaging assessment and may not always track OS
- Metastasis-free survival (MFS) — Key endpoint in non-metastatic CRPC (SPARTAN); accepted by FDA as clinically meaningful but demands extended imaging follow-up
- PSA response / kinetics — Convenient early pharmacodynamic signal but PSA can fluctuate from benign causes and is not a stand-alone approval endpoint
- Quality of life / patient-reported outcomes — Ensures survival gains are not offset by toxicity; subjective, so validated instruments and consistent administration are essential
How iNGENū runs prostate cancer trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Prostate Cancer clinical trials — FAQs
What are the key endpoints in modern prostate cancer trials?
How are genetic mutations changing prostate cancer treatment?
Why do prostate cancer trials commonly fail?
Ready to discuss your prostate cancer trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal